

Financial news for XENT dated on 2020-06-09: Intersect ENT Announces CMS Approves SINUVA Sinus Implant For Reimbursement With New C-Code And Pass-Through Payment Status

Financial news for XENT dated on 2020-05-12: SVB Leerink Maintains Market Perform on Intersect ENT, Raises Price Target to \$15

Financial news for XENT dated on 2020-05-12: JP Morgan Maintains Overweight on Intersect ENT, Lowers Price Target to \$18

Financial news for XENT dated on 2020-05-12: Canaccord Genuity Downgrades Intersect ENT to Hold

Financial news for XENT dated on 2020-05-11: Intersect ENT Announces \$65 Million Convertible Notes Investment from Deerfield Management

Financial news for XENT dated on 2020-05-11: Intersect ENT Q1 EPS \$(0.540) Misses \$(0.440) Estimate, Sales \$19.800M Miss \$23.660M Estimate

Financial news for XENT dated on 2020-04-15: Intersect ENT shares are trading lower after Bank Of America downgraded the stock from Buy to Underperform and announced a price target of \$10 per share.

Financial news for XENT dated on 2020-04-15: B of A Securities Downgrades Intersect ENT to Underperform, Announces \$10 Price Target

Financial news for XENT dated on 2020-04-13: Intersect ENT Sees Q1 Sales \$19.5M-\$19.8M; The Company Also Reported To Withdraw Full Year FY20 Guidance

Financial news for XENT dated on 2020-02-24: Intersect ENT ; Raises FY2020 Sales Guidance from \$115M-119M to \$115M-119M

Financial news for XENT dated on 2020-02-24: Intersect ENT Q4 EPS \$(0.25) Beats \$(0.35) Estimate, Sales \$31.754M Beat \$31.24M Estimate

Financial news for XENT dated on 2020-01-13: Intersect ENT Sees Prelim. FY19 Sales \$109M vs \$108.71M Est., Sees FY20 Sales \$115M-\$119M vs \$119.69M Est.

Financial news for XENT dated on 2019-12-20: JP Morgan Maintains Overweight on Intersect ENT, Raises Price Target to \$28

Financial news for XENT dated on 2019-11-27: Intersect ENT Appoints Richard A. Meier EVP And CFO

Financial news for XENT dated on 2019-11-01: Intersect ENT Reaffirms FY19 Sales Flat On Year Over Year Basis

Financial news for XENT dated on 2019-11-01: Intersect ENT Q3 EPS \$(0.41) Misses \$(0.39) Estimate, Sales \$24.056M Miss \$24.06M Estimate

Financial news for XENT dated on 2019-10-07: Intersect ENT shares are trading lower after the company's ASCENT trial did not meet its primary endpoint.

Financial news for XENT dated on 2019-10-07: Intersect ENT's ASCENT Trial Did Not Meet its Primary Endpoint

Financial news for XENT dated on 2019-10-07: Intersect ENT Shares Halted, News Pending

Financial news for XENT dated on 2019-08-02: Intersect ENT shares are trading lower after the company reported worse-than-expected Q2 EPS and sales results. The company's stock was also downgraded by multiple firms.

Financial news for XENT dated on 2019-08-02: Guggenheim Downgrades Intersect ENT to Neutral

Financial news for XENT dated on 2019-08-02: Piper Jaffray Downgrades Intersect ENT to Neutral, Lowers Price Target to \$17

Financial news for XENT dated on 2019-08-01: Intersect ENT Q2 EPS \$(0.36) Misses \$(0.34) Estimate, Sales \$26.7M Miss \$27.16M Estimate

Financial news for XENT dated on 2019-07-25: Intersect ENT Reports FDA Approval Of New PROPEL Mini Straight Delivery System

Financial news for XENT dated on 2019-07-10: Northland Securities Upgrades Intersect ENT to Market Perform

Financial news for XENT dated on 2019-06-27: Intersect ENT Reports CFO Jeryl Hilleman

To Step Down; Thomas West Named Pres, CEO

Financial news for XENT dated on 2019-06-21: Berenberg Downgrades Intersect ENT to Hold, Lowers Price Target to \$27

Financial news for XENT dated on 2019-06-04: Intersect ENT Highlights Publication Of Pooled Analysis of the SINUVA Sinus Implant for Nasal Polyps

Financial news for XENT dated on 2019-05-07: Intersect ENT shares are trading lower after SVB Leerink downgraded the stock from Outperform to Market Perform and lowered the price target from \$41 to \$29 following the company report of worse-than-expected Q1 EPS. The company also lowered its FY19 sale

Financial news for XENT dated on 2019-05-07: Northland Downgrades Intersect ENT, Inc. - Common Stock to Underperform

Financial news for XENT dated on 2019-05-07: SVB Leerink Downgrades Intersect ENT, Inc. - Common Stock to Market Perform, Lowers Price Target to \$29

Financial news for XENT dated on 2019-05-06: Intersect ENT shares are trading lower after the company reported lower-than-expected Q1 EPS results; the company also cut FY19 sales guidance.

Financial news for XENT dated on 2019-05-06: Intersect ENT Shares Down 11% Upon Resumption Of Trade

Financial news for XENT dated on 2019-05-06: Intersect ENT Reports CEO Lisa Earnhardt To Step Down; Kieran Gallahue Named Exec. Chair And Interim CEO

Financial news for XENT dated on 2019-05-06: Intersect ENT Shares To Resume Trade At 4:40 p.m. EDT

Financial news for XENT dated on 2019-05-06: UPDATE: Intersect ENT Cuts FY19 Sales Guidance From \$123M-\$127M To \$113M-\$117M vs \$ \$125.3M Estimate

Financial news for XENT dated on 2019-05-06: Intersect ENT Cuts FY19 Sales Guidance

Financial news for XENT dated on 2019-05-06: Intersect ENT Q1 EPS \$(0.35) Misses \$(0.3) Estimate, Sales \$26.673M Beat \$26.31M Estimate

Financial news for XENT dated on 2019-05-06: Intersect ENT Shares Halted News Pending

Financial news for XENT dated on 2019-04-29: Intersect ENT shares are trading higher after the company on Thursday announced it will present at the Bank of America Merrill Lynch Health Care Conference on Tuesday, May 14, 2019.

Financial news for XENT dated on 2019-02-25: Intersect ENT Sees Q1 Sales \$26M-\$26.5M vs \$27.5M Estimate; FY19 Sales \$123M-\$127M vs \$127.2M Estimate

Financial news for XENT dated on 2019-02-25: Intersect ENT Q4 EPS \$(0.16), Inline, Sales \$32.783M Beat \$32.49M Estimate

Financial news for XENT dated on 2019-01-07: Intersect ENT Sees Q1 Sales \$26.0M-26.50M vs \$28.36M Est

Financial news for XENT dated on 2019-01-07: Intersect ENT Sees FY2019 Sales \$123.0M-127.0M vs \$128.58M Est

Financial news for XENT dated on 2019-01-07: Intersect ENT Sees Q4 Sales \$32.60M-32.80M vs \$32.21M Est

Financial news for XENT dated on 2019-01-07: Intersect ENT Sees FY2018 Sales \$108.30M-108.50M vs \$107.93M Est

Financial news for XENT dated on 2018-12-17: Intersect ENT Announces First Patient Enrolled in ASCEND Study of Investigational Drug-Coated Sinus Balloon

Financial news for XENT dated on 2018-11-15: Intersect ENT Highlights Publication Of Pooled Analysis Of Steriod-Releasing Implants For Patients Following Frontal Sinus Surgery In International Forum of Allergy & Rhinology

Financial news for XENT dated on 2018-11-05: Intersect ENT Reaffirms FY2018 Sales Guidance of \$106.0M-109.0M vs \$107.36M Est

Financial news for XENT dated on 2018-11-05: Intersect ENT Q3 EPS \$(0.25) Beats \$(0.27) Estimate, Sales \$24.666M Beat \$24.1M Estimate

Financial news for XENT dated on 2018-10-29: Intersect ENT Names Christine Kowalski COO

Financial news for XENT dated on 2018-10-02: Documents Show Anthem Now Covering Reimbursement For Intersect's Sinuva

Financial news for XENT dated on 2018-08-03: Stocks Which Set New 52-Week Low Yesterday, August 2nd

Financial news for XENT dated on 2018-08-02: Stocks Which Set New 52-Week Low Yesterday, August 1st

Financial news for XENT dated on 2018-08-01: Intersect ENT Sees Q3 Sales \$23.8M-\$24.3M vs \$27.57M Est., FY18 Sales \$106M-\$109M vs \$116.29M Est.

Financial news for XENT dated on 2018-08-01: Intersect ENT Q2 EPS \$(0.14) Beats \$(0.17) Estimate, Sales \$26.3M Miss \$28.15M Estimate

Financial news for XENT dated on 2018-05-07: Piper Jaffray Publishes a Positive Note on Intersect ENT Calling the CMS' Decision an Error

Financial news for XENT dated on 2018-05-07: Hearing Leerink Also Positive on Intersect ENT

Financial news for XENT dated on 2018-05-07: Watch Shares of Intersect ENT Moving Higher, Hearing JP Morgan Positive on the Stock

Financial news for XENT dated on 2018-05-01: Intersect ENT Sees FY2018 Sales \$111.0M-116.0M vs \$115.40M Est

Financial news for XENT dated on 2018-05-01: Intersect ENT Q1 EPS \$(0.21) Beats \$(0.23) Estimate, Sales \$24.723M Beat \$23.65M Estimate

Financial news for XENT dated on 2018-04-02: Intersect ENT Announces Launch Of SINUVA Sinus Implant In-Office Treatment Option For Recurrent Nasal Polyps

Financial news for XENT dated on 2018-02-27: Intersect ENT Reports Q4 EPS \$(0.11) vs \$(0.18) Est., Sales \$29.53M vs \$28.71M Est.

Financial news for XENT dated on 2018-01-08: Intersect Sees Q1 Sales \$23.2M-\$23.7M vs \$24.4M Est.

Financial news for XENT dated on 2018-01-08: Intersect Sees FY18 Sales \$111M-\$116M vs \$113.8M Est.

Financial news for XENT dated on 2018-01-08: Intersect Sees Q4 Sales \$29.3M-\$29.5M vs \$27.7M Est.; Sees FY17 Sales \$96.1M-\$96.3M vs \$94.5M Est.

Financial news for XENT dated on 2018-01-02: JP Morgan Upgrades Intersect ENT to Overweight

Financial news for XENT dated on 2017-12-11: Intersect ENT Shares To Resume Trade At 8:30 a.m. EST

Financial news for XENT dated on 2017-12-11: Intersect ENT Reports FDA Approval Of SINUVA Sinus Implant As Treatment Option For Recurrent Nasal Polyps

Financial news for XENT dated on 2017-12-11: Shineco and Intersect ENT Halted News Pending

Financial news for XENT dated on 2017-12-11: Intersect ENT Shares Halted News Pending

Financial news for XENT dated on 2017-11-16: Deerfield Management Reports 5.9% Stake In Intersect ENT

Financial news for XENT dated on 2017-11-06: Intersect ENT Reports FDA Performed Pre-Approval Inspection Of Co.'s Menlo Park Facility

Financial news for XENT dated on 2017-11-02: Intersect ENT Sees Q4 Sales \$27.3M-\$27.8M vs \$26.89M Est.

Financial news for XENT dated on 2017-11-02: Intersect ENT Reports Q3 EPS \$(0.15) vs \$(0.19) Est., Sales \$22.3M vs \$21.51M Est.

Financial news for XENT dated on 2017-08-01: Intersect ENT Sees Q3 Sales \$21M-\$21.5M vs \$20.85M Est.; FY17 Sales \$91M-\$93M vs \$90.37M Est.

Financial news for XENT dated on 2017-08-01: Intersect ENT Reports Q2 EPS \$(0.08) vs \$(0.19) Est., Sales \$24M vs \$22.61M Est.

Financial news for XENT dated on 2017-05-31: Northland Securities Downgrades

Intersect ENT to Market Perform

Financial news for XENT dated on 2017-05-02: Intersect ENT Sees Q2 Sales \$22.5M-\$22.7M vs \$21.7M Est.; Raises FY17 Sales Outlook from \$87M-\$89M to \$89M-\$91M vs \$88M Est.

Financial news for XENT dated on 2017-05-02: Intersect ENT Reports Q1 EPS \$(0.23) vs \$(0.25) Est., Sales \$20.474M vs \$19.38M Est.

Financial news for XENT dated on 2017-03-08: Intersect ENT Submits NDA To FDA For Office-Based RESOLVE Steroid Releasing Implant

Financial news for XENT dated on 2017-03-06: Deutsche Bank Upgrades Intersect ENT To Buy, Raises Price Target To \$19

Financial news for XENT dated on 2017-02-28: Intersect ENT Reports Q4 EPS \$(0.17) vs \$(0.20) Est., Sales \$24.2M vs \$23.47M Est.

Financial news for XENT dated on 2017-02-24: Intersect ENT Reports FDA Approval of PROPEL Contour

Financial news for XENT dated on 2017-01-09: Intersect ENT Sees Prelim Q4 Rev. \$24-\$24.2M vs. Est. \$23M, FY16 Rev. \$78.5-\$78.7M vs. Est. \$77.4M

Financial news for XENT dated on 2016-12-07: Guggenheim Earlier Initiated Coverage On Intersect ENT at Buy, Announced \$20.00 Target

Financial news for XENT dated on 2016-11-02: JP Morgan Downgrades Intersect ENT, Inc. - Common Stock to Neutral

Financial news for XENT dated on 2016-10-06: Deutsche Bank Initiates Coverage on Intersect ENT at Hold

Financial news for XENT dated on 2016-03-29: Northland Securities Initiates Coverage on Intersect ENT at Outperform, Announces \$26.00 PT

Financial news for XENT dated on 2015-06-17: Leerink Swann Reiterates Outperform on Intersect ENT, Raises PT to \$38.00

Financial news for XENT dated on 2015-06-09: Canaccord Genuity Maintains Buy on Intersect ENT, Raises PT to \$32.00

Financial news for XENT dated on 2015-06-03: Intersect ENT Announces Prices Upsized 3.582M Share Offering @\$25.00/Share

Financial news for XENT dated on 2015-05-20: Intersect ENT Files S-1 Registration Statement for Proposed 3M Share Offering

Financial news for XENT dated on 2015-04-09: CRT Capital Initiates Coverage on Intersect ENT at Buy, Announces \$32.00 PT

Financial news for XENT dated on 2015-03-16: Canaccord Genuity Initiates Coverage on Intersect ENT at Buy, Announces \$27.00 PT

Financial news for XENT dated on 2015-01-12: Intersect ENT Sees FY2014 Sales \$38.40M-38.60M

Financial news for XENT dated on 2015-01-12: Intersect ENT Sees Q4 Sales \$13.20M-13.40M

Financial news for XENT dated on 2014-09-03: Intersect ENT, Inc. Reports Q2 EPS of \$(2.36) vs \$(0.28) Est; Revenue of \$8.57M vs \$8.46M Est

Financial news for XENT dated on 2014-08-18: Benzinga's Top Initiations

Financial news for XENT dated on 2014-08-18: JP Morgan Initiates Intersect ENT With Overweight

Financial news for XENT dated on 2014-08-18: JP Morgan Initiates Coverage on Intersect ENT, Inc. at Overweight, Announces \$22.00 PT

Financial news for XENT dated on 2014-08-18: Leerink Swann Initiates Coverage on Intersect ENT, Inc. at Outperform, Announces \$20.00 PT

Financial news for XENT dated on 2014-08-18: Piper Jaffray Initiates Coverage on Intersect ENT, Inc. at Overweight, Announces \$20.00 PT

Financial news for XENT dated on 2014-07-24: Intersect ENT Shares Open for Trade at \$13.20/Share, IPO Priced at \$11

Financial news for XENT dated on 2014-07-24: Intersect Announces 5M Share IPO Priced at \$11/Share

Financial news for XENT dated on 2014-07-21: IPO Lookout: Lots of Action This Week, But Is Anything A Worthwhile Investment?

Financial news for XENT dated on 2014-07-14: Intersect ENT Expects 5M Share IPO to Price \$11.00-\$13.00/Share